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Posttranslational modification with small ubiquitin-
like modifier (Sumo) regulates numerous cellular
and developmental processes. Sumoylation is dy-
namic with deconjugation by Sumo-specific prote-
ases (Senps) regulating steady-state levels. Different
Senps are found in distinct subcellular domains,
which may limit their deconjugation activity to coloc-
alizing Sumo-modified proteins. In vitro, Senps can
discriminate between the different Sumo paralogs:
Sumo1 versus the highly related Sumo2 and Sumo3
(Sumo2/3), which can form poly-Sumo chains. How-
ever, a full understanding of Senp specificity in vivo
is still lacking. Here, using biochemical and genetic
approaches, we establish that Senp1 has an ess-
ential, nonredundant function to desumoylate
Sumo1-modified proteins during mouse embryonic
development. Senp1 specificity for Sumo1 conju-
gates represents an intrinsic function and not simply
a product of colocalization. In contrast, Senp1 has
only a limited role in Sumo2/3 desumoylation,
although it may regulate Sumo1-mediated termina-
tion of poly-Sumo2/3 chains.
INTRODUCTION
Posttranslational modification of proteins with small ubiquitin-
like modifier (Sumo) is now established as an important mecha-
nism for modulating fundamental cellular and developmental
processes (Hannoun et al., 2010; Hay, 2005; Johnson, 2004; Lo-
melı´ and Va´zquez, 2011; Seeler et al., 2007). Recent evidence
suggests that the activity, subcellular localization, or stability of
sumoylated proteins is regulated by intra- and intermolecular
noncovalent interactions between Sumo and Sumo-interacting
motifs (SIMs) (Geiss-Friedlander and Melchior, 2007; Kerscher
et al., 2006; Wang and Dasso, 2009). Multiple Sumo paralogs
are found in mammals, the almost identical and immunologically1640 Cell Reports 3, 1640–1650, May 30, 2013 ª2013 The Authorsindistinguishable Sumo2 and Sumo3 (Sumo2/3), and the more
distantly related Sumo1. Proteomic studies have shown that
some proteins are modified only by Sumo1, others only by
Sumo2/3, and some by any or all of the three paralogs (Rosas-
Acosta et al., 2005; Vertegaal et al., 2006). In addition, Sumo2/
3 can form chains through conjugation to an internal lysine (Ver-
tegaal, 2010). Because it lacks this lysine, Sumo1 addition pre-
vents further chain elongation (Matic et al., 2008). Each of these
mono- and poly-Sumo modifications likely represents a func-
tionally distinct signal.
Although the consequences of Sumomodification are diverse,
some paradigms have emerged in the regulation of sumoylation.
The single E2-conjugating enzyme, Ubc9, can directly transfer
Sumo to some substrates. A limited number of Sumo E3 ligases
expand the substrate repertoire. Sumo-SIM interactions also
play an important role in Sumo paralog and substrate specificity,
allowing hundreds of different target proteins to be selectively
conjugated (Gareau and Lima, 2010; Wang and Dasso, 2009;
Wilkinson and Henley, 2010). Steady-state levels are also regu-
lated by desumoylation. Six Sumo-specific proteases (Senp1–
Senp3 and Senp5–Senp7) are found in mouse and human; these
carry out deconjugation as well as processing of immature Sumo
precursor proteins. Their carboxy-terminal regions encode a
highly conserved catalytic domain, but in vitro studies have
shown that Senps can discriminate between Sumo paralogs in
deconjugation and have different capabilities and specificities
in processing (Hay, 2007; Mukhopadhyay and Dasso, 2007;
Wang and Dasso, 2009). These properties suggest that Senps
make an important contribution to overall specificity of steady-
state sumoylation. Senp amino-terminal domains have limited
sequence similarity, and whereas little is known about their func-
tion, they are thought to direct subcellular localization and,
thereby, mediate specificity through colocalization with specific
targets (Drag and Salvesen, 2008; Hay, 2007).
Senp1 is most closely related to Senp2, and in vitro studies
have shown that each can deconjugate Sumo1 or Sumo2/3-
modified forms of model sumoylated proteins (Reverter and
Lima, 2004, 2006; Shen et al., 2006). However, a recent study
examining binding of synthetic Sumo derivatives by endogenous
Senps in lysates of human cells suggested that only Senp1 has
Figure 1. Similar Phenotypes of Senp1 Mu-
tants
(A) An E12.5 WT embryo and two Senp1M1/M1
(M1) littermates on 129S6 (129) inbred back-
ground. The mutant embryo in the middle shows
pooling of blood in the abdominal region (arrow).
Mutant embryo at right arrested at E11.5 or
earlier.
(B) 129S6/C57Bl6 background (mixed) E13.5 WT
embryo and M1 littermate, showing pooling of
blood in the abdominal region (arrow).
(C) Mixed background E9.5 WT embryo and
Senp1Gt/Gt (Gt) littermate. The mutant arrested
prior to embryonic turning.
(D) 129S6 background E10.5 WT embryo and Gt
littermate. The mutant arrested earlier.
(E) 129S6 background E12.5 WT embryo and Gt
littermate. The mutant is developmentally delayed
and shows pooling of blood in the abdominal re-
gion (arrow).
(F) Mixed background E13.5 WT and Gt littermate.
The mutant shows pooling of blood in the
abdominal region (arrow).
See also Table S1.specificity toward Sumo1 (Kolli et al., 2010). Here, we examine
Senp1 specificity in the developing mouse embryo using two
distinctSenp1mutant alleles: one a loss of function and the other
stably expressing only the amino-terminal half, which is devoid of
catalytic activity. Both alleles are prenatal lethal and lead to
accumulation of Sumo1-modified proteins in homozygous em-
bryos. Importantly, lysis of mutant embryos under conditions in
which Senps retain activity reveals a significant fraction of
Sumo1-modified proteins still sumoylated. The inability of the re-
maining Senps to deconjugate this fraction even under condi-
tions in which cellular proteins are no longer restricted to distinct
subcellular locations suggests that only Senp1 has intrinsic
specificity for these Sumo1 targets. Genetically reducing
Sumo1 levels rescues Senp1mutant embryos to birth, indicating
that Senp1 is required only to maintain proper Sumo1 steady-
state levels and, surprisingly, is nonessential for Sumo2/3 desu-
moylation. Analysis of the Senp1 amino-terminal truncation has
revealed that misexpression of this domain has a significant ef-
fect on Sumo2/3 dynamics and decreases Senp2 protein levels,
suggesting that Senp1 itself may regulate Senp2 posttransla-
tionally and providing evidence that Senp2 is an important
Sumo2/3 desumoylase in embryonic development.
RESULTS
Two Distinct Mouse Senp1Mutant Alleles Show Similar
Phenotypes
We previously reported a prenatal lethal insertional mutation in
the mouse Senp1 gene caused by exogenous proviral integra-Cell Reports 3, 1640–165tion into the first intron (Yamaguchi et al.,
2005). Embryos homozygous for this
mutant allele, Senp1M1Mku (hereafter
referred to as Senp1M1), show pheno-
typic abnormalities beginning at embry-onic day (E) 11.5 with the majority dying between E12.5 and
E14.5 (Figures 1A and 1B; Table S1). A subsequently published
analysis of a different allele, Senp1Gt(XG001)Byg (hereafter
referred to as Senp1Gt), suggested that Senp1 mutant embryos
die later, between E13.5 and E15.5 (Cheng et al., 2007). In order
to take advantage of both alleles to gain insight into Senp1
specificity, we first addressed these apparent phenotypic
differences. To directly compare Senp1Gt to Senp1M1, we
generated mice from the same XG001 gene trap ES cells
used by Cheng et al. (2007) and maintained the line on the
129S6 genetic background, congenic with Senp1M1 animals,
or as mixed 129S6/C57Bl6. As expected, matings between
Senp1Gt heterozygous animals failed to produce homozygous
offspring. Surprisingly, analysis of both mixed and inbred back-
ground embryos revealed a number of homozygotes arresting
or showing defects at or prior to E10.5 (Figures 1C and 1D;
Table S1). This is much earlier than what was reported by
Cheng et al. (2007) and earlier than the defects seen in Senp1M1
mutants (Table S1). However, most Senp1Gt/Gt embryos survive
past this stage but then develop abnormalities, most notably
pooling of blood in the abdominal region (Figures 1E and 1F, ar-
rows), which are identical to defects seen in Senp1M1 homozy-
gotes at the same stages (Figure 1B, arrow). Very few Senp1Gt
mutants on the inbred background survive past E12.5. How-
ever, mixed background embryos survive somewhat longer,
perhaps explaining the later embryonic death previously
reported by Cheng et al. (2007). Overall, our analysis points
to the Senp1M1 and Senp1Gt alleles as having very similar
phenotypic outcomes.0, May 30, 2013 ª2013 The Authors 1641
Figure 2. Status of Sumo-Modified Proteins
in Senp1 Mutants
(A) Immunoblots (IB) of SDS or NP-40 lysates ofWT,
M1, or Gt embryos detected with anti-Sumo1.
HMM Sumo1 conjugates accumulate at steady
state in M1 embryos (upper panel, lane 2), and free
Sumo1 levels are reduced (middle panel, lane 2).
The majority of HMM Sumo1 conjugates are re-
tained upon NP-40 lysis of M1 embryos (upper
panel, lane 4). Increased free Sumo1 in NP-40 ly-
sates (middle panel, lanes 3 and 4) is due to
postlysis desumoylation. Gt embryos accumulate
HMM Sumo1 conjugates at steady state (upper
panel, lane 6) and show reduced free Sumo1 and
increased unprocessed Sumo1 (middle panel, lane
6, arrowhead). HMM Sumo1 conjugates are re-
tained upon NP-40 lysis of Gt embryos (upper
panel, lane 9) similar to M1 embryos (upper panel,
lane 8). Lower panels show detection with anti-actin
to control for equal loading. Molecular weights in
kilodaltons (kDa) are shown to the left of panels.
(B) Immunoblots of SDS or NP-40 lysates of WT,
M1, or Gt embryos detected with anti-Sumo2/3.
Similar amounts of total proteinwere loaded in lanes
1–4 to show that the majority of HMM Sumo2/3
conjugates (lane 1, upper panel) are lost upon NP-
40 lysis (lane 3), with only a few very HMM species
retained in the M1 mutant (lane 4, bracket). Lower
amounts of protein and shorter exposures reveal a
lack of accumulation of HMM Sumo2/3 conjugates
at steady state in M1 mutants (upper panel, lanes 5
and 6). However, free Sumo2/3 levels at steady
state are reduced (middle panel, compare lanes 1
and 2 and lanes 5 and 6). Unlike M1, Gt embryos
accumulate HMM Sumo2/3 conjugates at steady
state (upper panel, lane 8), as well as showing
reduced free Sumo2/3 levels (middle panel, lane 8).
NP-40 lysates of Gt (lane 10) show retention ofHMM
species similar to those seen in M1 (lane 4).
(C) HEK293 cells transfected with pyo-Senp1
(Senp1) or the active site mutant (C599S) were
either lysed in SDS or Triton buffer and then directly
immunoblotted or immunoprecipitated (IP) with
anti-pyo. Anti-Senp1 detects full-length protein
(lanes 1 and 2, arrow) as well as three HMM species in C599S lysates (lane 2, arrowheads). The same three HMM species are detected with anti-Sumo2/3 in
Triton (lane 8, arrowheads) or SDS immunoprecipitates (lane 10, arrowheads) of C599S lysates, indicating that these are sumoylated forms of Senp1. A very
HMM smear is seen only in Triton (lane 8, bracket), indicating that these are associated proteins. Anti-Sumo1 detects Sumo1-modified proteins in Triton (lane 4)
but not SDS immunoprecipitates (lane 6) of C599S lysates, indicating that these are associated proteins. Asterisks (*) mark nonspecific bands.
See also Figures S1 and S2.Senp1 Is the Primary Activity for Desumoylation of
Sumo1-Modified Proteins
To address the function of Senp1 in desumoylation, we used
immunoblotting to analyze the status of Sumo1 and Sumo2/3
conjugates in congenic Senp1M1 and Senp1Gt homozygous em-
bryos, isolated at E10.5–E11.5 andwithout overt defects.Whole-
embryo extracts were made either in 4% SDS or 1% NP-40
buffer. SDS completely inactivates Senps, providing a snapshot
of the steady-state levels of all sumoylated proteins at the time of
lysis. As shown in Figure 2, sumoylated proteins inwild-type (WT)
embryos are represented by a smear of bands of high molecular
mass (HMM) in immunoblots detected with either anti-Sumo1
(Figure 2A, lanes 1 and 5, upper panel) or anti-Sumo2/3 anti-
serum (Figure 2B, lanes 1, 5, and 7, upper panel). In contrast,1642 Cell Reports 3, 1640–1650, May 30, 2013 ª2013 The AuthorsNP-40 lysis does not inactivate Senps, although normal cellular
compartmentalization is disrupted. Consequently, sumoylated
proteins are exposed to enzymatically active Senps in a nonphy-
siological manner and become deconjugated postlysis. Immu-
noblotting reveals the loss of HMM bands (Figure 2A, lanes 3
and 7, upper panel; Figure 2B, lanes 3 and 9, upper panel) and
an increase in free Sumo (Figures 2A and 2B, compare lanes 1
and 3, middle panels).
SDS lysates of Senp1M1/M1 or Senp1Gt/Gt embryos show an in-
crease in HMM Sumo1 conjugates compared to WT embryos
(Figure 2A, compare lanes 1 and 2, 5, and 6, upper panels) and
a corresponding decrease in free unconjugated Sumo1 (middle
panels). A slightly slower migrating form of free Sumo1 was
seen in Senp1Gt mutant embryo lysates (Figure 2A, lane 6,
middle panel, arrowhead), consistent with a reduction in Sumo1
processing. HMM Sumo1 conjugates also were found to accu-
mulate in lysates of mouse embryonic fibroblasts (MEFs) derived
from Senp1Gt/Gt or Senp1M1/M1 embryos (Figure S1A). Immuno-
fluorescence of MEFs revealed Sumo1 accumulation predomi-
nately in the nucleus of Senp1 mutant cells (Figures S1B–S1E).
This increase in steady-state Sumo1 conjugate levels and
decrease in free Sumo1 indicate that under physiological condi-
tions, no other Senp can compensate for loss of Senp1 function
to carry out Sumo1 desumoylation. To address whether this is
due to the lack of colocalization of other Senps with Sumo1-
modified proteins, we examined lysates made in NP-40 buffer.
Strikingly, although Senps are active in these conditions, thema-
jority of Sumo1 conjugates do not undergo postlysis desumoyla-
tion in mutant lysates (Figure 2A, lanes 4, 8, and 9). To provide
evidence that the lack of desumoylation is not because these
conjugates are protected from deconjugation by aggregation
or association with other factors, we added back Senp1 activity
by mixing mutant and WT lysates at various ratios (Figure S1F).
Quantification of HMM conjugates showed a significant re-
duction beyond that expected from dilution alone. Similarly,
the corresponding increase in free Sumo1 levels was greater
than expected from just mixing (Figure S1G). Thus, the HMM
conjugates in mutant lysates can indeed be desumoylated if
exposed to Senp1 activity. This indicates that Senps other
than Senp1 lack the intrinsic ability to deconjugate a significant
fraction of Sumo1-modified proteins.
Senp1 Has Only a Limited Role in Sumo2/3
Deconjugation
Analysis of the steady-state levels of Sumo2/3-modified proteins
in Senp1M1/M1 embryos showed no changes compared to WT
(Figure 2B, compare lanes 1 and 2, 5 and 6, upper panels),
although there is a small decrease in free Sumo2/3 (middle
panels).We also found no difference in Sumo2/3 immunofluores-
cence comparing WT and Senp1M1 mutant MEFs (Figures S2B–
S2E). In contrast, SDS lysates of Senp1Gt/Gt embryos show
increased levels of HMM Sumo2/3 conjugates compared to
WT (Figure 2B, compare lanes 7 and 8, upper panels), and
Senp1Gt mutant MEFs show an increase in Sumo2/3 in the nu-
cleus (Figures S2F–S2I). These differing results leave unan-
swered the question of whether Senp1 has physiological
Sumo2/3 targets. However, in contrast to what we found for
Sumo1-modified proteins, the vast majority of Sumo2/3 conju-
gates in either Senp1 mutant undergo postlysis desumoylation
in NP-40 buffer (Figure 2B, compare lane 2 with 4 and lane 8
with 10, upper panels). This suggests that if Senp1 does have
physiological Sumo2/3 targets, other Senps have the intrinsic
ability to also desumoylate these proteins.
To gain further insight into whether Senp1 can indeed target
Sumo2/3-modified proteins, we took advantage of previous find-
ings showing that human SENP1 carrying a cysteine to serine
substitution in the active site (SENP1 C602S) forms trapped in-
termediates with SUMO1-conjugated substrates and that these
can be coimmunoprecipitated (Bailey and O’Hare, 2004). We
recently generated a mouse Senp1 expression vector with a
similar active site mutation (Senp1 C599S) carrying an amino-
terminal polyoma-epitope tag (Sharma et al., 2010). FollowingCtransfection of pyo-Senp1 C599S or control WT pyo-Senp1
into HEK293 cells, we lysed cells in mild Triton X-100 buffer
with iodoacetamide to inhibit desumoylation and then immuno-
precipitated with anti-pyo antibody. To confirm that mouse
Senp1 C599S coimmunoprecipitates endogenous human
SUMO1-sumoylated proteins, we immunoblotted with anti-
Sumo1. This analysis revealed a number of discrete bands
across the full range of molecular masses (Figure 2C, lane 4).
This result is consistent with Senp1 having a large variety of
Sumo1-modified substrates in the mouse embryo. We then im-
munoblotted with anti-Sumo2/3 but detected only three major
species (Figure 2C, lane 8, arrowheads) and a faint smear of
very HMM coimmunoprecipitates (Figure 2C, lane 8, bracket).
The three major species were identical in molecular mass to
slower migrating forms of Senp1 seen in direct immunoblotting
of the active site mutant (Figure 2C, lane 2, arrowheads). To
confirm that these bands represent SUMO2/3-conjugated forms
of pyo-Senp1 C599S and not coimmunoprecipitating SUMO2/3-
modified substrates, we repeated the immunoprecipitations
using lysates prepared in 3%SDS to eliminate protein-protein in-
teractions. Following dilution of the SDS lysates and anti-pyo
immunoprecipitation, we carried out anti-Sumo2/3 immunoblot-
ting and were again able to detect the three major species (Fig-
ure 2C, lane 10, arrowheads), indicating that these are covalently
SUMO2/3-modified forms of Senp1. As expected, anti-Sumo1
immunoblotting no longer detected any coimmunoprecipitates
(Figure 2C, lane 6). These results support the majority of physio-
logical substrates for Senp1 being Sumo1-modified proteins and
suggest that the only major Sumo2/3 substrate is Senp1 itself.
Senp1Gt Mutants Express a Truncated Senp1 Affecting
Sumo2/3 Levels
The aforementioned findings are hard to reconcile with the
increased steady-state levels of HMM Sumo2/3-modified pro-
teins found in Senp1Gtmutant embryos (Figure 2B, lane 8). How-
ever, the answer may lie in the differences between these two
Senp1 mutant alleles. The Senp1M1 allele results from retroviral
insertion into an enhancer element leading to vastly reduced
transcriptional levels (Yamaguchi et al., 2005). Senp1Gt results
from a gene trap insertion into intron 8 (Figure 3A), theoretically
leading to the first 309 amino acids of Senp1 protein being ex-
pressed as a fusion with the b-galactosidase (b-gal)/neomycin
resistance (b-geo) selectable marker encoded by the gene trap
vector. This Senp1-b-geo fusion protein would be nonfunctional
for enzymatic activity due to the lack of the carboxy-terminal
catalytic domain. However, it would retain the entire amino half
of Senp1, known to include a nuclear localization signal (Bailey
and O’Hare, 2004). Stable expression of this truncated Senp1
fusion could have a trans-acting effect.
To confirm expression of the Senp1-b-geo fusion protein, we
first immunoblotted with polyclonal antisera raised against full-
length Senp1, which detects a band of approximately 73 kDa
in WT embryo lysates (Figure 3B, lanes 1 and 3, arrowhead).
This 73 kDa band was not detected in homozygous Senp1M1
or Senp1Gt embryo lysates (Figure 3B, lanes 2 and 4). However,
a species of approximately 180 kDa was found uniquely in
Senp1Gt (Figure 3B, lane 4, arrow). This is the expected size of
the first 309 amino acids of Senp1 fused to b-geo. Furtherell Reports 3, 1640–1650, May 30, 2013 ª2013 The Authors 1643
Figure 3. Structure, Expression, and Inter-
fering Activity of the SenpGt Allele
(A) Schematic representation of the entire Senp1
locus showing the M1 retroviral vector insertion in
intron 1 and the gene trap vector insertion in intron
8. A close-up of the structure of the XG001 gene
trap insertion is shown in the middle. Shown below
is the fusion transcript resulting from splicing from
exon 8 to the splice acceptor (sa) of the b-geo
cassette.
(B) Immunoblots of lysates of WT, M1, or Gt em-
bryos detected with anti-Senp1 raised against full-
length (FL) protein (lanes 1–4) or against a carboxy-
terminal peptide (C-P) (lanes 5 and 6), or anti-b-gal
(lanes 7 and 8). The 73 kDa Senp1 protein (arrow-
heads) is not detected in either mutant. The 180 kDa
band (arrows) detected with both anti-Senp1 (FL)
and anti-b-gal represents Senp1 exons 1–8 fused to
b-geo. Asterisks (*) mark nonspecific bands.
(C) Immunoblots of lysates of WT or M1MEFs either
mock infected (lanes 1 and 2), or infected with
Senp11–309-EGFP retroviral vector (lanes 3 and 4, 7
and 8) or control EGFP-only vector (lanes 5 and 6).
Top panels show detection with anti-Senp1. Ar-
rowheads indicate endogenous Senp1 protein, and
arrows indicate the Senp11–309-EGFP fusion pro-
tein. Lanes 5–8 in the upper-middle panels show
detection with anti-GFP. Lower-middle panels
show detection with anti-Sumo2/3. Expression of
Senp11–309-EGFP results in significantly higher
Sumo2/3 steady-state levels only in M1 MEFs
(lanes 4 and 8). Bottom panels show detection of
anti-actin to control for equal loading.
See also Figure S3.analysis with anti-peptide antisera raised against amino acids
361–425 in the carboxy half of Senp1 failed to detect this
180 kDa species (Figure 3B, lane 6), consistent with it containing
only the amino half. Immunoblotting with antisera against b-gal
also detected a 180 kDa species, consistent with this represent-
ing the fusion protein (Figure 3B, lane 8, arrow).
We next assessed whether expression of the Senp1 amino-
terminal half can affect Sumo2/3 steady-state levels in another
cellular context. We constructed a retroviral vector to express
the same truncation of Senp1 but fused to EGFP (Senp11–309-
EGFP). We then infected WT and Senp1M1/M1 MEFs, which
lack detectable Senp1 protein (Figure 3C, top panels, lanes 2,
4, 6, and 8; Figure S3D). Whereas endogenous full-length
Senp1 was found in both the nucleus and cytoplasm (Fig-
ure S3A), Senp11–309-EGFP was exclusively nucleoplasmic
(Figures S3B and S3E). This is likely due to the absence of the
nuclear export signals found in the carboxy half of Senp1 (Kim
et al., 2005). Strong nuclear rim localization was apparent in
Senp1M1/M1 MEFs with low Senp11–309-EGFP expression (Fig-
ure S3E, arrow). Immunoblotting showed that overall levels of1644 Cell Reports 3, 1640–1650, May 30, 2013 ª2013 The AuthorsSenp11–309-EGFP (Figure 3C, top panels,
lanes 3, 4, 7, and 8, arrows) were compa-
rable to endogenous Senp1 protein (Fig-
ure 3C, top panels, lanes 1, 3, 5, and 7,
arrowheads) but far lower than controlEGFP expression (Figure 3C, upper-middle panels, compare
lanes 5 and 6 with lanes 7 and 8). In mutant MEFs regardless
of Senp11–309-EGFP expression levels, we found a significant
accumulation of Sumo2/3 conjugates (Figure 3C, lower-middle
panels, lanes 4 and 8). Changes in Sumo2/3 levels were less
apparent in WT MEFs expressing Senp11–309-EGFP (Figure 3C,
lower-middle panels, lanes 3 and 7) and were not seen in
MEFs expressing EGFP alone (Figure 3C, lower-middle panels,
compare lanes 5 and 6 with lanes 1 and 2). Thus, in the absence
of detectable WT Senp1 protein, even a small amount of the
amino-terminal half of Senp1 is sufficient to affect Sumo2/3
steady-state levels, providing an explanation for the changes
seen in Senp1Gt embryos.
Expression of the Amino Half of Senp1 Reduces Senp2
Levels
The increase in steady-state levels of Sumo2/3-modified pro-
teins found in Senp1Gt embryos or upon expression of the trun-
cated Senp1 fusion protein in MEFs is either due to decreased
deconjugation or increased conjugation. It is known that a variety
Figure 4. Truncated Senp1 Affects Senp2
Expression
(A) Immunoblots of lysates from E10.5 Gt mutant
embryos (lanes 1 and 2) or MEFs (lanes 3 and 4), or
M1 mutant MEFs (lanes 5 and 6) detected with
anti-Senp2. Senp2 levels are significantly lower in
Gt but are not affected in M1.
(B) Immunoblots of HEK293 cells transfected with
EGFP-SENP2 fusion alone (lanes 1 and 3) or co-
transfected with FLAG-SENP11–300 (lanes 2 and
4), detected with anti-GFP (upper panel) or anti-
Senp1 (middle panel). EGFP-SENP2 levels are
significantly reduced in the presence of FLAG-
SENP11–300 (lane 2). Reduced levels are no longer
seen following MG132 treatment (lane 4), indi-
cating that FLAG- SENP11–300 enhances protea-
somal turnover of EGFP-SENP2. Lower panel
shows anti-actin to control for equal loading.
(C) EGFP fluorescence showing that transfected
EGFP-SENP2 localizes predominantly around the
nuclear rim (arrowheads) and within subjacent
nuclear bodies (arrows).
(D) DAPI staining of the same nucleus.
(E) EGFP fluorescence showing that nuclear rim
localization of EGFP-SENP2 is lost in cells co-
transfected with FLAG- SENP11–300.
(F) DAPI staining of the same nucleus.
See also Figure S4.of cellular stresses can induce upregulation of Sumo2/3 conju-
gation (Tempe´ et al., 2008). Therefore, we examined phospho-
p38 MAP kinase (T180/Y182), phospho-Akt (S473), and Hsp70
as indicators of stress (Cuenda and Rousseau, 2007; Konishi
et al., 1997; Silver and Noble, 2012; Yung et al., 2011) but found
no changes in Senp1Gt compared to WT embryos (Figure S4A).
Thus, it seems unlikely that Sumo2/3 steady-state levels in-
crease due to a stress response-dependent induction of sumoy-
lation. Another possible mechanism for how stable expression of
the amino-terminal half could affect Sumo2/3 desumoylation
would be through binding of substrates targeted by other Senps,
thereby sequestering or otherwise inhibiting their deconjugation.
However, as we showed above, full-length Senp1 fails to bind
Sumo2/3-modified proteins to any significant degree, suggest-
ing that it has few if any targets, shared or otherwise. Indeed,
we were not able to coimmunoprecipitate any Sumo2/3 conju-
gates following expression of mouse Senp11–309-EGFP in
MEFs (Figure S4B, lane 4) or of a similar truncation, FLAG
epitope-taggedhumanSENP11–300, inHEK293cells (FigureS4C,
lane 4). This indicates that if there is an effect of the Senp1 amino
half on Sumo2/3 deconjugation, it is not through shared sub-
strate binding and sequestration.
As an alternative explanation, we asked if expression of trun-
cated Senp1might affect the expression of other Senps. Indeed,
we found that levels of the most closely related Sumo protease,
Senp2, are significantly reduced in Senp1Gtmutant embryos and
MEFs (Figure 4A, compare lanes 1 and 2 and lanes 3 and 4). This
is not due simply to the absence of functional Senp1 because
Senp1M1 mutant embryos or MEFs show no reduction in
Senp2 levels (Figure 4A, lane 6). To explore the mechanism for
this effect, we first determined that expression of FLAG-
SENP11–300 in HEK293 cells also leads to significantly reducedCexpression of a human EGFP-SENP2 fusion (Hang and Dasso,
2002) in cotransfection experiments (Figure 4B, upper panel,
lane 2). We then repeated the cotransfection in the presence of
the proteasome inhibitor MG132 and found that EGFP-SENP2
levels were no longer affected by FLAG-SENP11–300 coexpres-
sion (Figure 4B, lane 4). This finding suggests that expression
of the amino half of Senp1 accelerates proteasomal turnover of
Senp2. As previously reported (Hang and Dasso, 2002), EGFP-
SENP2 localizes to the nuclear rim (Figure 4C, arrowheads)
and subjacent subnuclear domains (Figure 4C, arrows). How-
ever, these specific domains of expression are not apparent in
HEK293 cells coexpressing FLAG-SENP11–300 (Figure 4E).
These results suggest that expression of truncated Senp1 leads
to displacement of Senp2 from its normal localization sites and
subsequent destabilization.
Evidence for Senp1 Deconjugating Terminal Sumo1
Moieties on Poly-Sumo2/3 Chains
The aforementioned results resolve the issue of why Sumo2/3
steady-state conjugate levels increase in Senp1Gt mutant em-
bryos and provide further support for a limited role normally for
Senp1 in the bulk of Sumo2/3 deconjugation. However, the
handful of very HMM Sumo2/3-modified proteins seen in NP-
40 lysates made from either Senp1 mutant allele (Figure 2B,
lanes 4 and 10, brackets) and the faint smear of HMM species
coimmunoprecipitating with Senp1 C599S (Figure 2C, lane 8,
bracket) suggest some unique and essential function for Senp1
in Sumo2/3 dynamics. Given their size, we suspected that these
HMM species might be proteins conjugated with long poly-
Sumo2/3 chains. Senp1 was recently shown to deconjugate
Sumo2/3 chains in vitro (Be´ke´s et al., 2011). However, other
Senps also have been implicated in Sumo2/3 chain editingell Reports 3, 1640–1650, May 30, 2013 ª2013 The Authors 1645
Figure 5. Senp1 Is Required to Remove Terminal Sumo1Moieties on
Sumo2/3 Chains
Immunoblots of SDS lysates fromM1MEFs infected with HA-Sumo2 retroviral
expression vector (lanes 2, 4, 6, and 8) or empty HA vector (lanes 1, 3, 5, and 7).
Direct analysis with anti-HA (lane 2) or anti-HA immunoblotting of anti-HA
immunoprecipitates (lane 4) shows HA-Sumo2/3 conjugates across the full
range of molecular masses. Analysis of anti-HA immunoprecipitates with anti-
Sumo1 (lane 8) reveals only HMM species (bracket), suggesting that these
represent long poly-Sumo2/3 chains capped with Sumo1.(Lima and Reverter, 2008), and these redundant activities should
be able to carry out postlysis deconjugation of Sumo2/3 chains
in NP-40 buffer. An alternative explanation is that these are
poly-Sumo2/3 chains capped with Sumo1 (Matic et al., 2008),
and Senp1 is required to remove Sumo1 to allow chain short-
ening. As evidence for these HMM species being Sumo1-cap-
ped Sumo2/3 chains, they should be detected by anti-Sumo1
immunoblotting of anti-Sumo2/3 immunoprecipitates. Proteins
conjugated with Sumo2/3 and Sumo1 at different lysine residues
would also be expected from this experiment. However, these
should be distributed along the entire range of molecular
masses, whereas poly-Sumo2/3 chains should be HMM.
Because of the technical difficulty of immunoprecipitating
Sumo2/3-modified proteins directly from embryos with available
anti-Sumo2/3 polyclonal antiserum,we introduced a hemaggluti-
nin (HA) epitope-tagged Sumo2 into Senp1M1/M1 MEFs. The
MEFs provide a good model for Senp1M1 mutant embryos
because they show a similar loss of the bulk of Sumo2/3 conju-
gates in NP-40 lysates compared to SDS (Figure S2A), retaining
only a few HMM species (Figure S2A, lane 4, bracket). HA
epitope-tagged Sumo2 expressed from a retroviral vector (Arria-
gadaetal., 2011)wasconjugatedontoproteinsdistributedacross
the entire range of molecular masses, as revealed either by direct
immunoblottingwithanti-HA (Figure5, lane2)orbyanti-HA immu-
noprecipitation followed by anti-HA immunoblotting (Figure 5,
lane 4). In contrast, only HMM species were found in anti-
Sumo1 immunoblots of theanti-HA immunoprecipitates (Figure5,
lane 8), consistent with proteins conjugated with long poly-
Sumo2/3 chains cappedwith Sumo1. The HMMspecies retained
in NP-40 lysates of Senp1 mutant embryos likely have a similar
configuration. Thus, Senp1 may be uniquely required to remove
this terminal Sumo1 for chain dismantling to proceed efficiently.
Genetically Reducing Sumo1 Rescues Senp1
Developmental Defects
Taken together, the aforementioned findings support an essen-
tial role for Senp1 only in Sumo1 deconjugation, either directly
from target proteins or from Sumo2/3 chains. To provide conclu-
sive evidence for a Sumo1-specific essential function, we uti-1646 Cell Reports 3, 1640–1650, May 30, 2013 ª2013 The Authorslized the Sumo1 mutant mouse line (Evdokimov et al., 2008).
Sumo1 heterozygotes have reduced levels of HMM Sumo1 con-
jugates compared to WT (Figure 6A, compare lanes 1 and 2 and
lanes 5 and 6), suggesting a genetic approach to restore normal
Sumo1 levels in Senp1 mutants. We bred the Sumo1 mutant
allele into the Senp1M1 and Senp1Gt strains to obtain homozy-
gous Senp1 mutant embryos also heterozygous for Sumo1.
Anti-Sumo1 or anti-Sumo2/3 immunoblot analysis of lysates
from E12.5 embryos showed that Sumo1 heterozygosity indeed
prevents the accumulation of HMM Sumo1 conjugates in
Senp1M1/M1 (Figure 6A, compare lanes 3 and 4) and Senp1Gt/Gt
embryos (Figure 6A, compare lanes 7 and 8) but has no effect
on levels of Sumo2/3 conjugates (Figure 6B).
Halving the Sumo1 gene dose not only overcomes the exces-
sive accumulation of Sumo1 conjugates found in both mutants,
but it also leads to prolonged viability (Figure 6C). Sumo1 hetero-
zygosity rescued all Senp1M1 mutants well past the stages at
which they would otherwise die, whereas approximately two-
thirds of Senp1Gt/Gt Sumo1+/ embryos were rescued (Table
1). We also allowed these matings to go to term and found
both Senp1M1 and Senp1Gt pups that were overtly normal, but
most were either stillborn or died soon after birth (Table 1). Pa-
thology done on these individuals has pointed to respiratory de-
fects. Thus, whereas genetically reducing Sumo1 levels rescues
the Senp1 prenatal lethal mutant phenotype, confirming that
Senp1 function is required only for Sumo1 deconjugation during
development, there may be a more expansive requirement for
Senp1 in the perinatal period and the adult.
DISCUSSION
The work reported here establishes an essential function for
Senp1 during mouse development in maintaining appropriate
steady-state levels of Sumo1 modification, validating and
expanding on recent studies in human cells and in Xenopus
embryos that showed only Senp1 has specificity for synthetic
Sumo1 derivatives (Kolli et al., 2010; Wang et al., 2009). Our
work also sheds light on the degree to which Senp specificity
is a product of restricted colocalization. As we show, no other
Senp can act redundantly to carry out desumoylation of
Sumo1 in the absence of Senp1, although Senp2 can deconju-
gate Sumo1 in vitro (Shen et al., 2006) and is expressed in the
embryo at appropriate stages (Magdaleno et al., 2006). The min-
imal postlysis desumoylation of the Sumo1 proteome in NP-40
lysates of Senp1 mutants argues that Senp2 and the other re-
maining Senps have only a limited capacity to deconjugate
Sumo1-modified proteins. This suggests that Sumo1-modified
proteins accumulate in Senp1 mutants not because of the lack
of colocalization with any other Senp, but because only Senp1
has the intrinsic capability to carry out Sumo1 deconjugation. It
is likely that the nonconserved sequence regions of Senp1,
which are predominantly found in the amino half, confer this
intrinsic specificity. It will be of interest to determine whether
this domain contains Sumo1-specific SIMs unique to Senp1.
Although we have obtained evidence for Senp1 regulating
Sumo2/3 chain length through deconjugation of Sumo1 from
the ends of poly-Sumo2/3 chains, ultimately, a mass spectrom-
etry-based approach will be required to provide definitive proof.
Figure 6. Sumo1 Heterozygosity Rescues
Senp1 Mutant Defects
(A) Immunoblots of SDS lysates from E12.5 em-
bryos detected with anti-Sumo1. Lanes 1–4 show
WT,Sumo1 heterozygote (Sumo1+/),Senp1M1/M1
(M1), and Senp1M1/M1 Sumo1+/ (M1 Sumo1+/);
lanes 5–8 show WT, Sumo1+/, Senp1Gt/Gt (Gt),
and Senp1Gt/Gt Sumo1+/ (Gt Sumo1+/). Sumo1
heterozygosity significantly lowers accumulation
of Sumo1 conjugates in mutant embryos
(compare lanes 3 and 4 and lanes 7 and 8).
Molecular weights in kilodaltons (kDa) are shown
to the left of each panel. Lower panels show anti-
actin immunoblots to control for equal loading.
(B) Immunoblots of SDS lysates from E12.5 em-
bryos detected with anti-Sumo2/3. The same
samples were analyzed and loaded in the same
order as in (A).
(C) Left panel shows an E14.5 Senp1M1/M1
Sumo1+/ embryo that was viable when dissected
and a dead Senp1M1/M1 littermate. Right panel
shows a rescued E15.5 Senp1Gt/Gt Sumo1+/
embryo and a dead Senp1Gt/Gt littermate.However, our work clearly shows a surprisingly limited role for
Senp1 in Sumo2/3 dynamics. Although the Senp1 active site
mutant can coimmunoprecipitate a variety of Sumo1-modified
proteins, which are presumed to be trapped intermediates, it
has no such ability with Sumo2/3 conjugates. This suggests
that the lack of change in steady-state levels of HMM Sumo2/
3-modified proteins in Senp1M1 mutant embryos and cells is
not because other Senps can act redundantly but is instead
due to Senp1 having a limited repertoire of physiological
Sumo2/3 substrates. Interestingly, Senp1 itself appears to be
the major Sumo2/3 target. It will be important to determine the
consequences of Sumo2/3 sumoylation for Senp1 activity and
whether, given its major function in Sumo1 deconjugation, modi-
fication of Senp1 allows it to serve as a nexus in crosstalk
between the Sumo1 and Sumo2/3 pathways.Cell Reports 3, 1640–165Senp1Gt is clearly not a simple loss-of-
function allele as previously proposed by
Cheng et al. (2007). Our analysis shows
that the amino half of Senp1 is stably
expressed from this allele and that this
truncated form can act in trans to affect
Sumo2/3 levels in various cellular con-
texts. Several lines of evidence also point
to truncated Senp1 affecting Senp2
expression, likely at the posttranslational
level. One explanation for why the
Senp1Gt allele acts recessively and why
enforced expression of the Senp1 trunca-
tion does not affect Senp2 levels in WT
MEFs stems from our observation that
Senp11–309 is specifically found at the
nuclear rim only in Senp1M1 mutant
MEFs. Previous work has provided evi-
dence for human SENP2 localizing to
the nucleoplasmic side of the nuclearpore complex (Hang and Dasso, 2002; Zhang et al., 2002).
Senp1 has also been found specifically at the nuclear envelope
in certain cell types (Bailey and O’Hare, 2004), and recent evi-
dence indicates that both Senps interact with the nucleoporin
Nup153 (Chow et al., 2012). WT Senp1 may outcompete
Senp11–309 for binding to Nup153, explaining why the truncated
form is not found at the nuclear pore in WT MEFs. Thus, only in
the absence of WT protein can Senp11–309 bind Nup153, but
the association may not be as dynamic as for WT Senp1 due
to the lack of nuclear export signals found in the carboxy half
(Kim et al., 2005). This may in turn affect Senp2 binding of
Nup153. It will be an important avenue of future research to
determine the role of Nup153 in the destabilization of Senp2 by
truncated Senp1 and whether Senp1 normally regulates Senp2
levels through Nup153.0, May 30, 2013 ª2013 The Authors 1647
Table 1. Rescue of Senp1 Mutants by Sumo1 Heterozygosity
Senp1 Genotype
Strain Stage +/+ +/ / / Phenotype
Senp1M1 Sumo1+/ E14.5–E16.5 15 38 16 all normal
P0 9 17 9 4 stillborn
Senp1Gt Sumo1+/ E14.5–E16.5 12 22 15 5 dead/dying
P0 16 21 7 6 stillborn
The number of embryos or pups from crosses within the Senp1M1 Sumo1
or Senp1Gt Sumo1 strains listed by Senp1 genotype (WT, +/+; heterozy-
gous, +/; homozygous, /). All individuals were heterozygous for
Sumo1 mutation. Sumo1 heterozygosity rescues 100% of Senp1M1 mu-
tants past E14.5. The number of Senp1M1/M1 Sumo1+/ individuals found
at birth also matches Mendelian expectations. Most pups nursed and
survived more than 1 day. For Senp1Gt/Gt Sumo1+/, rescue is incom-
plete, and the majority of rescued pups were found dead on P0.The correlation of reduced Senp2 stability with increased
steady-state levels of Sumo2/3 conjugates in Senp1Gt mutants
suggests that Senp2 is an important Sumo2/3 desumoylase in
the mouse embryo. The likely consequences of this accumula-
tion of Sumo2/3 conjugates are the severe defects seen in a small
subset of Senp1Gt mutants. These occur at developmentally
earlier stages than the defects found in Senp1M1mutants, which
accumulate only Sumo1-modified proteins. Most Senp1Gt mu-
tants escape these early defects, perhaps because Sumo2/3
levels are still at or below a critical threshold allowing their further
development. However, they eventually succumb to phenotypic
abnormalities identical to theSumo1-dependent defects found in
Senp1M1 mutants. This may explain why the majority of Senp1Gt
mutants can be rescued by genetic reduction of Sumo1; the frac-
tion not rescued likely representing the same subset that accu-
mulates Sumo2/3 conjugates above the critical threshold. Their
Sumo2/3-dependent defects cannot be overcome by lowering
Sumo1 levels. These twodifferent phenotypic classes ofSenp1Gt
mutants provide insight into how perturbations in the steady-
state levels of the different Sumo paralogs can have quite
different developmental outcomes, supporting the idea that
Sumo1 and Sumo2/3 are functionally distinct signals.
Our results also may inform the debate on the so-called
‘‘Sumo enigma’’ or how for most proteins, only a small fraction
is sumoylated at steady state yet can affect the total pool (Hay,
2005). Many of the proposed explanations posit rounds of su-
moylation and desumoylation to regulate formation and/or turn-
over of protein complexes (Hay, 2005; Wilkinson and Henley,
2010). Even in the absence of Senp1, there may still be some,
albeit reduced, level of dynamic cycling between Sumo1-modi-
fied and -unmodified forms. However, the fact that lowering
input levels of Sumo1 alone can rescue the Senp1 phenotype
also suggests the possibility that, at least in some circum-
stances, the proper functional outcome of sumoylation may be
the product of specific, and low, steady-state levels.
EXPERIMENTAL PROCEDURES
Mice and Embryo Analysis
XG001 ES cells were obtained from the Mutant Mouse Regional Resource
Center. Chimeric mice were made by blastocyst injection following standard
protocols. Congenic lines were generated in six backcross generations using1648 Cell Reports 3, 1640–1650, May 30, 2013 ª2013 The Authorsgenome-wide marker-assisted selection. Embryos were dissected at different
stages (day of plug detection considered E0.5), washed in cold PBS (without
Ca2+ and Mg2+), and then either fixed in 4% paraformaldehyde at 4C over-
night for phenotype analysis, or frozen immediately for later processing or
placed in SDS or NP-40 lysis buffer. PCR genotyping of Senp1M1 embryos
and mice was described previously by Yamaguchi et al. (2005). To genotype
Senp1Gt mice, the approximate point of insertion of the gene trap vector
350 bp downstream of exon 8 was determined by PCR using a forward primer
located within Senp1 exon 8 and various reverse primers located 300 bp apart
along the length of the 1.5 kb intron 8. For PCR genotyping, the WT allele was
amplified using the exon 8 forward primer and a reverse primer located down-
stream of the insertion site, and the gene trap allele with the exon 8 forward
primer and a reverse primer located within the gene trap vector. Primer se-
quences are available upon request. Animal studies were approved by the
NCI-Frederick Animal Care and Use Committee and conducted in accordance
with the Public Health Service Policy for the Care and Use of Laboratory Ani-
mals using procedures outlined in the National Research Council Guide for
Care and Use of Laboratory Animals.
Immunoblotting and Antibodies
Individual embryo protein extracts were prepared using either SDS buffer
(250 mM Tris-HCl [pH 6.8], 4% SDS, 10% glycerol, 10 mM iodoacetamide,
and protease inhibitor cocktail [Roche]), or NP-40 buffer (50 mM Tris-HCl
[pH 8.0], 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and
protease inhibitor cocktail). SDS lysates were incubated at room temperature
for 5 min followed by sonication and centrifugation. NP-40 lysates were kept
on ice for 30 min followed by sonication and centrifugation. Equivalent
amounts of protein extracts, as determined using a modified Bradford assay
(Bio-Rad Laboratories), were fractionated by SDS-PAGE using 8%–16%
Tris-Glycine gels (Invitrogen), transferred to nitrocellulose membranes using
semidry electrophoretic transfer (Hoefer), and processed as described
previously by Yamaguchi et al. (2005). Primary antibodies used were rabbit
polyclonal anti-Sumo1, rabbit polyclonal anti-Sumo2, and rabbit polyclonal
anti-Senp1 (Azuma et al., 2003, 2005), rabbit polyclonal anti-b-gal (AbD Sero-
tec), rabbit polyclonal anti-GFP (Invitrogen), rabbit polyclonal anti-FLAG
(Sigma-Aldrich), rabbit polyclonal anti-phospho-p38 MAP kinase and rabbit
monoclonal anti-phospho-Akt (Ser473) (Cell Signaling Technology), rabbit
polyclonal anti-heat shock protein 70 (Stressgen), and mouse monoclonal
anti-Senp1 and rabbit polyclonal anti-Senp2 (Santa Cruz Biotechnology).
Mouse monoclonal anti-b-actin (Sigma-Aldrich) was used to confirm equiva-
lent protein loading. Detection of secondary antibody-horseradish peroxidase
conjugates was done using ECL Plus substrate (GEHealthcare) or SuperSignal
West Pico solution (Pierce).
MEFs
MEFs were prepared from individual E11.5 or E12.5 embryos and cultured in
3% oxygen as described previously by Yamaguchi et al. (2005). Total protein
extracts were prepared by suspending MEFs in 62.5 mM Tris-HCl (pH 6.8) and
10 mM iodoacetamide, then adding an equal amount of 23 SDS buffer
(62.5 mM Tris-HCl [pH 6.8], 6% SDS, 10% glycerol, 10 mM iodoacetamide,
and protease inhibitors). Extracts were incubated at room temperature for
5min followed by sonication and centrifugation and processed for immunoblot
analysis as described above for embryo extracts. High-titer stocks of helper-
free retrovirus, generated by transient transfection of HA-Sumo2 retroviral
vector into Phoenix Ampho packaging cells, were used to infect MEFs as
described previously by Yamaguchi et al. (2005). Stable cell lines were estab-
lished by selection in 50 mg/ml Hygromycin. HA-Sumo2 conjugates were
immunoprecipitated from cell lysates prepared in 23 SDS sample buffer and
diluted ten times with Triton X-100 buffer (50 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 1 mM EDTA, 0.5% Triton X-100, 10 mM iodoacetamide, and protease
inhibitors). Diluted lysates were precleared with Protein G Sepharose beads
(GE Healthcare) for 1 hr at 4C followed by incubation with rat monoclonal
anti-HA antibody (Roche; Clone 3F10) at 4C. After overnight incubation,
immunoprecipitates were washed three times with 1 ml of Triton X-100 buffer,
resuspended in 23 SDS sample buffer, and analyzed by immunoblotting
utilizing light-chain-specific secondary antibody (Jackson ImmunoResearch).
Immunofluorescence analysis was carried out as previously described by
Evdokimov et al. (2008). Senp11–309-EGFP was visualized based on GFP sig-
nals, whereas endogenous Senp1 was detected using mouse monoclonal
anti-Senp1 (1:50 dilution). Rabbit polyclonal anti-Sumo1 (Evdokimov et al.,
2008) was used at 1:20 dilution and anti-Sumo2 at 1:500 dilution.
Coimmunoprecipitation of the Senp1 Active Site Mutant
HEK293 cells were cultured in DMEM (Invitrogen) supplemented with 10%
heat-inactivated fetal bovine serum and antibiotics. Pyo-Senp1 or pyo-
Senp1 C599S constructs (Sharma et al., 2010) were transiently transfected
into exponentially growing cells using Lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer’s instructions. For coimmunoprecipitation,
cells were lysed in ice-cold Triton X-100 buffer and kept on ice for 30 min fol-
lowed by centrifugation. Equivalent amounts of protein extracts were pre-
cleared with Protein G Sepharose beads for 1 hr at 4C followed by incubation
with mouse monoclonal anti-pyo antibody (gift from Deborah Morrison, NCI,
Frederick, MD, USA) and Protein G Sepharose beads for 4 hr at 4C. After
incubation, immunoprecipitates were washed three times with 1 ml of Triton
X-100 buffer, resuspended in 23 SDS sample buffer, and analyzed by im-
munoblotting. MG132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal; Sigma-
Aldrich) treatment was carried out at 10 mM final concentration for 12 hr.
Senp11–309-EGFP Fusion Construct and Retroviral Infection
Senp1 exons 1–8 were PCR amplified from a full-lengthmouse cDNA. Forward
and reverse primers included EcoR1 and Nhe1 restriction sites, respectively.
EGFP was PCR amplified using pEGFP-N1 (Clontech) as template. Forward
primer contained an Nhe1 site, and reverse primer contained a Sal1 site and
stop codon. Three-way ligation was carried out with the EcoR1/Nhe1 Senp1
cDNA PCR product, Nhe1/Sal1-digested PCR-amplified EGFP fragment,
and EcoR1/Sal1-digested pBabePuro. Control EGFP vector was constructed
by PCR amplification of EGFP sequences from pEGFP-N1 using a forward
primer containing an EcoR1 site and the same reverse primer. The EcoR1
and Sal1-digested PCRproduct was ligated into EcoR1/Sal1-digested pBabe-
Puro. Restriction analysis and DNA sequencing confirmed each retroviral vec-
tor construct. High-titer stocks of helper-free retrovirus were generated by
transient transfection of Phoenix Ampho packaging cells. Infected MEFs
then underwent selection in 2 mg/ml puromycin.
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